References
- Highlights of prescribing information for Keytruda. Merck.com. Dec, 1 2021. www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf.
- Merck provides update on KEYTRUDA® (Pembrolizumab) indication in metastatic small cell lung cancer in the US. Merck.com. Mar 1, 2021. www.merck.com/news/merck-provides-update-on-keytruda-pembrolizumab-indication-in-metastatic-small-cell-lung-cancer-in-the-us/.
- Su C, Wang H, Li Y, Guo Q, Zhang L, Li J. Adverse effects of anti-PD-1/PD-L1 therapy in non-small cell lung cancer. Front Oncol. 2020:10. doi:10.3389/fonc.2020.554313.
- Micaily I, Chernoff M. An unknown reaction to pembrolizumab: Giant Cell arteritis. Ann Oncol. 2017;28(10):2621–2622. doi:10.1093/annonc/mdx306.
- Narala R, Reddy SA, Mruthyunjaya P. Giant cell arteritis manifesting as retinal arterial occlusion and paracentral acute middle maculopathy in a patient on pembrolizumab for metastatic uveal melanoma. Am J Ophthalmol Case Rep. 2020;20:100891. doi:10.1016/j.ajoc.2020.100891.
- Couette N, Paul J. Giant cell arteritis associated with PD-1 inhibition. BMJ Case Rep. 2021;14(11):e246443. doi:10.1136/bcr-2021-246443.
- Keytruda. National Cancer Institute. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/keytruda.
- Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. Aug, 1990;33(8):1122–1128. doi:10.1002/art.1780330810.
- O'Keefe GD, Bunya VY, Halfpenny C, Megalla M. Ocular and orbital complications of checkpoint inhibitors. EyeWiki. Jun 3, 2021; https://eyewiki.aao.org/Ocular_and_Orbital_Complications_of_Checkpoint_Inhibitors.
- Grzybowski A, Justynska A. Giant cell arteritis with normal ESR and/or CRP is rare, but not unique! Eye. 2013;27(12):1418–1419. doi:10.1038/eye.2013.208.
- Martins P, Teixeira V, Teixeira FJ, Canastro M, Palha A, Fonseca JE, et al. Giant cell arteritis with normal inflammatory markers: case report and review of the literature. Clin Rheumatol. 2020;39:3115–3125. doi:10.1007/s10067-020-05116-1.
- Hayreh SS. Ophthalmic features of giant cell arteritis. Baillieres Clin Rheumatol. Dec, 1991;5(3):431–459. doi:10.1016/s0950-3579(05)80064-0. PMID: 1807820.
- Connolly BP, Krishnan A, Shah GK, Whelan J, Brown GC, Eagle RC Jr, et al. Characteristics of patients presenting with central retinal artery occlusion with and without giant cell arteritis. Can J Ophthalmol. Dec 2000;35(7):379–384. doi:10.1016/s0008-4182(00)80125-8. PMID: 11192446.
- Hayreh SS, Podhajsky PA, Zimmerman B. Occult giant cell arteritis: ocular manifestations. Am J Ophthalmol. 1998;125(4):521–526. doi:10.1016/S0002-9394(99)80193-7.
- Chacko JG, Chacko JA, Salter, MW. Review of Giant cell arteritis. Saudi J Ophthalmol. 2014. doi:10.1016/j.sjopt.2014.10.001.
- Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA. Checkpoint inhibitor immune therapy. Retina. 2018;38(6):1063–1078. doi:10.1097/iae.0000000000002181.
- Deitch-Harel I, Raskin E, Habot-Wilner Z, Friling R, Amer R, Kramer M. Uveitis induced by biological agents used in cancer therapy. Ocul Immunol Inflamm. 2020;29(7–8):1370–1374. doi:10.1080/09273948.2020.1760310.
- Guedj M, Quéant A, Funck-Brentano E, Kramkimel N, Lellouch J, Monnet D, et al. Uveitis in patients with late-stage cutaneous melanoma treated with Vemurafenib. JAMA Ophthalmol. 2014;132(12):1421. doi:10.1001/jamaophthalmol.2014.3024.
- Conrady CD, Larochelle M, Pecen P, Palestine A, Shakoor A, Singh A. Checkpoint inhibitor-induced uveitis: a case series. Graefes Arch Clin Exp Ophthalmol. 2017;256(1):187–191. doi:10.1007/s00417-017-3835-2.